Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | AR-42 + Pazopanib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AR-42 | HDAC42 | HDAC Inhibitor 41 | AR-42 is a histone deacetylase (HDAC) inhibitor, which may lead to increased apoptosis of tumor cells and decreased tumor growth (PMID: 23178755, PMID: 21778190). | |
Pazopanib | Votrient | GW-786034 | FGFR1 Inhibitor 24 FGFR2 Inhibitor 18 FGFR3 Inhibitor 13 KIT Inhibitor 52 PDGFR Inhibitor (Pan) 27 VEGFR Inhibitor (Pan) 33 | Votrient (pazopanib) inhibits VEGFR-1, -2 and -3, KIT, and PDGFR, and FGFR1, 2, and 3, leading to decreased tumor angiogenesis and growth (PMID: 17620431, PMID: 23786770). Votrient (pazopanib) is approved for renal cell carcinoma and soft tissue sarcoma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02795819 | Phase I | AR-42 + Pazopanib | Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer | Terminated | USA | 0 |